KALA BIO, Inc.

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.29 on 9 Oct 2026

0 buys6 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$26.98M

Free cash flow

$31.99M

Return on equity

-385.7%

Return on capital

-49.6%

Debt to equity

7.91

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
23 Oct 2025	Iwicki Mark T Director	Sold at will	$125.46K	59.9%
23 Oct 2025	Reumuth Mary CHIEF FINANCIAL OFFICER	Sold at will	$792.94	3.2%
22 Oct 2025	Bazemore Todd Director	Sold at will	$39.65K	57.1%
22 Oct 2025	Brazzell Romulus K SEE REMARKS	Sold at will	$38.80K	56.5%
22 Oct 2025	Reumuth Mary CHIEF FINANCIAL OFFICER	Sold at will	$26.75K	51.9%
22 Oct 2025	Kharabi Darius CHIEF BUSINESS OFFICER	Sold at will	$17.27K	33.3%

18out of 100

Profitability 25

Financial strength 42

Growth 0

Insiders 0

Strongest on financial strength (42), weakest on insiders (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$248.73K

6 sales

Planned sales

under a 10b5-1 plan